MetaStat

MetaStat Shares Outstanding

The The number of shares of MetaStat (MTST) as of Oct 20, 2026 is 5.43 M. In the previous year, The number of shares was 5.43 M — a change of 0.00% (lower).

Shares Outstanding

5.43 M

YoY

0.00%

Last updated:

In 2018, MetaStat had 5.43 M outstanding stocks, a 0.00% change from the 5.43 M stocks in the previous year.

The MetaStat Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2011
0.03 USD
Jan 1, 2012
1.08 USD
Jan 1, 2013
1.39 USD
Jan 1, 2014
5.43 M USD
Jan 1, 2015
5.43 M USD
Jan 1, 2016
5.43 M USD
Jan 1, 2017
5.43 M USD
Jan 1, 2018
5.43 M USD
The MetaStat Shares Outstanding history
YEARShares OutstandingYoY
5.43 M0.00%
5.43 M0.00%
5.43 M0.00%
5.43 M0.00%
5.43 M+389.69 M%
1.39+28.91%
1.08+3,500.00%
0.030.00%
0.030.00%
0.03+50.00%
0.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MetaStat Number of shares

MetaStat shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2011
30,000.00 Stocks
Jan 1, 2012
1.08 M Stocks
Jan 1, 2013
1.39 M Stocks
Jan 1, 2014
1.41 M Stocks
Jan 1, 2015
1.66 M Stocks
Jan 1, 2016
1.82 M Stocks
Jan 1, 2017
2.97 M Stocks
Jan 1, 2018
5.43 M Stocks

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating MetaStat's Shares Outstanding

MetaStat's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in MetaStat’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding MetaStat’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in MetaStat’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about MetaStat stock

The number of shares of MetaStat is 5.43 M in 2018.

The number of shares of MetaStat changed from 5.43 M to 5.43 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares MetaStat since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Other — MetaStat

Shares OutstandingSupply ChainNet Debt per ShareAssets per Share

All Key Metrics — MetaStat